Oncolytic viruses, like IMLYGIC and DELYTACT approved for melanoma and malignant glioma, are being researched by major companies for new cancer treatments, including Genelux'

Oncolytic viruses, RNA or DNA, are promising cancer treatments, targeting and destroying cancer cells while stimulating the immune system. FDA-approved therapies IMLYGIC and DELYTACT target melanoma and malignant glioma, respectively. Major companies like Replimune, Genelux, and Imugene are researching new oncolytic virus treatments, with Genelux's Olvi-Vec in Phase III for platinum-resistant ovarian cancer and Replimune's RP1 in development.

July 01, 2024
3 Articles